Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

Acquisition of the constitutively active Janus kinase 2 (JAK2)V617F mutation occurs in almost all patients with polycythaemia vera (PV) and in a significant number of patients with essential ...

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic dermatitis, according to a new study presented at the American Academy of ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

The essential thrombocythemia market is on a growth trajectory, driven by increasing diagnosis rates, aging population ...

The cash injection comes as Ajax has been cleared by the US FDA to start clinical trials of AJ1-11095, which Ajax says will be the first type 2 JAK2 inhibitor to be tested in human subjects.

Intact receptor knockin and knockout approaches and receptor constructs without the Jak2 binding domain demonstrate a) a requirement for the PRLR for there to be PRL- driven internalization of GHR, ...